We chose lung fibrosis as our model disease because p16Ink4a+ cells have been previously reported to arise de novo in the fibrotic lung (19, 20, 26, 30), but the therapeutic role for existing senolytics is less clear. The gene discussed is CDKN2A; the disease is pulmonary fibrosis.